---
title: "SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252024097.md"
datetime: "2025-08-07T11:33:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252024097.md)
  - [en](https://longbridge.com/en/news/252024097.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252024097.md)
generator: "portal-rs"
---

# SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -1.09.

### Segment Revenue

-   **Grant Revenue**: No revenue was recognized for the three and six months ended June 30, 2025, compared to $263,137 and $1,207,712 for the same periods in 2024, respectively.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended June 30, 2025, was - $10,114,270, compared to - $7,335,455 for the same period in 2024. For the six months ended June 30, 2025, the net loss was - $15,311,043, compared to - $12,361,200 for the same period in 2024.
-   **Research and Development Expenses**: Increased by 2.6% to $6,996,660 for the three months ended June 30, 2025, compared to $6,822,198 for the same period in 2024. For the six months ended June 30, 2025, expenses slightly decreased by 0.8% to $14,653,981 from $14,769,253 in 2024.
-   **General and Administrative Expenses**: Decreased by 24.9% to $2,735,401 for the three months ended June 30, 2025, compared to $3,642,637 for the same period in 2024. For the six months ended June 30, 2025, expenses decreased by 27.2% to $5,850,182 from $8,030,773 in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: Decreased to - $14,948,761 for the six months ended June 30, 2025, from - $18,467,790 for the same period in 2024.
-   **Net Cash Provided by (Used in) Investing Activities**: Increased to $9,868,940 for the six months ended June 30, 2025, from - $20,140,390 for the same period in 2024.
-   **Net Cash Used in Financing Activities**: Decreased to - $347,829 for the six months ended June 30, 2025, from - $715,457 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to advance its lead product candidate, SAB-142, into a Phase 2b clinical trial called the SAFEGUARD study, with the intent to use the data as supportive evidence for future regulatory approval.
-   **Non-Core Business**: The company does not expect to generate revenues during the development phase of its primary pipeline development target of Type 1 diabetes, which remains independently financed as it explores potential partnerships, co-development opportunities, and licensing arrangements.

### Related Stocks

- [SABSW.US](https://longbridge.com/en/quote/SABSW.US.md)

## Related News & Research

- [Southern Copper (NYSE:SCCO) Shares Up 8.3%  - Still a Buy?](https://longbridge.com/en/news/296638179.md)
- [Trump Boosted INTC and DELL: Now He Says ‘Do Magnets’—Are MP and USAR Stocks Next?](https://longbridge.com/en/news/296591886.md)
- [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md)
- [MSH Capital Advisors LLC Acquires New Shares in Chevron Corporation $CVX](https://longbridge.com/en/news/296598647.md)
- [Longfellow Investment Management Co. LLC Takes $2.07 Million Position in Bank of America Corporation $BAC](https://longbridge.com/en/news/296593233.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**